Antagonism of cytotoxic chemotherapy in neuroblastoma cell lines by 13-cis-retinoic acid is mediated by the antiapoptotic Bcl-2 family proteins

Molecular Cancer Therapeutics

Volumn 9, Issue 12, 2010, Pages 3164-3174

  Hadjidaniel, Michael D ^a   Reynolds, C Patrick ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CISPLATIN; DOXORUBICIN; ETOPOSIDE; ISOTRETINOIN; MELPHALAN; PROTEIN BCL 2; PROTEIN BCL XL; TOPOTECAN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MINIMAL RESIDUAL DISEASE; MITOCHONDRIAL MEMBRANE POTENTIAL; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ALKYLATING AGENTS; APOPTOSIS; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; CISPLATIN; CYTOCHROMES C; CYTOPROTECTION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ETOPOSIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOTRETINOIN; MELPHALAN; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; NEUROBLASTOMA; NITROPHENOLS; PIPERAZINES; PROTECTIVE AGENTS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; SIGNAL TRANSDUCTION; SULFONAMIDES; TOPOISOMERASE INHIBITORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78650423565     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0078     Document Type: Article

References (45)

1. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-73.
2. Reynolds CP. Detection and treatment of minimal residual disease in high-risk neuroblastoma. Pediatr Transplant 2004;8:56-66.
3. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas- Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A children's oncology group study. J Clin Oncol 2009;27:1007-13.
4. McCaffery PJ, Adams J, Maden M, Rosa-Molinar E. Too much of a good thing: Retinoic acid as an endogenous regulator of neural differentiation and exogenous teratogen. Eur J Neurosci 2003;18: 457-72.
5. Lotan R. Retinoids in cancer chemoprevention. Faseb J 1996;10: 1031-9.
6. Zhou Q, Stetler-Stevenson M, Steeg PS. Inhibition of cyclin D expression in human breast carcinoma cells by retinoids in vitro. Oncogene 1997;15:107-15.
7. Chen YH, Lavelle D, Desimone J, Uddin S, Platanias LC, Hankewych M. Growth inhibition of a human myeloma cell line by all-trans retinoic acid is not mediated through downregulation of interleukin-6 receptors but through upregulation of p21(WAF1). Blood 1999;94:251-9.
8. Borriello A, Cucciolla V, Criscuolo M, Indaco S, Oliva A, Giovane A, et al. Retinoic acid induces p27Kip1 nuclear accumulation by modulating its phosphorylation. Cancer Res 2006;66:4240-8.
9. Amatruda TT, Sidell N, Ranyard J, Koeffler HP. Retinoic acid treatment of human neuroblastoma cells is associated with decreased N-myc expression. Biochem Biophys Res Commun 1985;126:1189-95.
10. Thiele CJ, Reynolds CP, Israel MA. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 1985;313:404-6.
11. Daftary GS, Taylor HS. Endocrine regulation of HOX genes. Endocr Rev 2006;27331-55.
12. Lasorella A. Differentiation of neuroblastoma enhances Bcl-2 expression and induces alterations of apoptosis and drug resistance. Cancer Res 1995;15:15.
13. Lombet A, Zujovic V, Kandouz M, Billardon C, Carvajal-Gonzalez S, Gompel A, et al. Resistance to induced apoptosis in the human neuroblastoma cell line SK-N-SH in relation to neuronal differentiation. Role of Bcl-2 protein family. European Journal of Biochemistry 2001;268:1352-62.
14. Reynolds CP, Lemons RS. Retinoid therapy of childhood cancer. Hematol Oncol Clin North Am 2001;15:867-910.
15. Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ. Retinoid therapy of high-risk neuroblastoma. Cancer Lett 2003;197:185-92.
16. Reynolds CP, Schindler PF, Jones DM, Gentile JL, Proffitt RT, Einhorn PA. Comparison of 13-cis-retinoic acid to trans-retinoic acid using human neuroblastoma cell lines. Prog Clin Biol Res 1994;385:237-44.
17. Reynolds CP, Kane DJ, Einhorn PA, Matthay KK, Crouse VL, Wilbur JR, et al. Response of neuroblastoma to retinoic acid in vitro and in vivo. Prog Clin Biol Res 1991;366:203-11.
18. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999;94: 1192-200.
19. Adamson PC, Wilson C. Potentiation of cytotoxic drugs with concomitant exposure to retinoids in neuroblastoma. Proc Am Assoc Cancer Res 2006;97:4873.
20. Benn SC, Woolf CJ. Adult neuron survival strategies-slamming on the brakes. Nat Rev Neurosci 2004;5:686-700.
21. Keshelava N, Seeger RC, Groshen S, Reynolds CP. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 1998;58: 5396-405.
22. Reynolds CP, Wang Y, Melton LJ, Einhorn PA, Slamon DJ, Maurer BJ. Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide. Med Pediatr Oncol 2000;35:597-602.
23. Collins PJ, Hennessy LK, Leibelt CS, Roby RK, Reeder DJ, Foxall PA. Developmental validation of a single-tube amplification of the 13 CODIS STR loci, D2S1338, D19S433, and amelogenin: The AmpFlSTR Identifiler PCR Amplification Kit. J Forensic Sci 2004;49: 1265-77.
24. Reynolds CP, Biedler JL, Spengler BA, Reynolds DA, Ross RA, Frenkel EP, et al. Characterization of human neuroblastoma cell lines established before and after therapy. J Natl Cancer Inst 1986;76: 375-87.
25. Frgala T, Kalous O, Proffitt RT, Reynolds CP. A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther 2007; 6:886-97.
26. Khan AA, Villablanca JG, Reynolds CP, Avramis VI. Pharmacokinetic studies of 13-cis-retinoic acid in pediatric patients with neuroblastoma following bone marrow transplantation. Cancer Chemother Pharmacol 1996;39:34-41.
27. Bennett CL, Sinkule JA, Schilsky RL, Senekjian E, Choi KE. Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. Cancer Res 1987;47: 1952-6.
28. Boos J, Krumpelmann S, Schulze-Westhoff P, Euting T, Berthold F, Jurgens H. Steady-state levels and bone marrow toxicity of etoposide in children and infants: Does etoposide require age-dependent dose calculation? J Clin Oncol 1995;13:2954-60.
29. Hersh MR, Ludden TM, Kuhn JG, Knight WA. Pharmacokinetics of high dose melphalan. Invest New Drugs 1983;1:331-4.
30. Pinguet F, Martel P, Fabbro M, Petit I, Canal P, Culine S, et al. Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation. Anticancer Res 1997;17:605-11.
31. Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, et al. Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 1992;10: 647-56.
32. Sabbagh R, Leclerc JM, Sunderland M, Theoret Y. Chronopharmacokinetic of a 48-hr continuous infusion of doxorubicin to children with acute lymphoblastic leukemia. Proc Am Assoc Cancer Res 1993;34: 198.
33. Tubergen DG, Stewart CF, Pratt CB, Zamboni WC, Winick N, Santana VM, et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: A pediatric oncology group study. J Pediatr Hematol Oncol 1996;18:352-61.
34. Keshelava N, Groshen S, Reynolds CP. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. Cancer Chemother Pharmacol 2000;45:1-8.
35. Ghanem L, Steinman R. A proapoptotic function of p21 in differentiating granulocytes. Leuk Res 2005;29:1315-23.
36. Mukherjee SB, Das M, Sudhandiran G, Shaha C. Increase in cytosolic Ca2+ levels through the activation of non-selective cation channels induced by oxidative stress causes mitochondrial depolarization leading to apoptosis-like death in Leishmania donovani promastigotes. J Biol Chem 2002;277:24717-27.
37. Yang B, Keshelava N, Anderson CP, Reynolds CP. Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine. Cancer Res 2003;63:1520-6.
38. Piqueras B, Autran B, Debre P, Gorochov G. Detection of apoptosis at the single-cell level by direct incorporation of fluorescein-dUTP in DNA strand breaks. Biotechniques 1996;20:634-40.
39. Adrain C, Creagh EM, Martin SJ. Apoptosis-associated release of Smac/DIABLO from mitochondria requires active caspases and is blocked by Bcl-2. EMBO J 2001;20:6627-36.
40. Cui H, Schroering A, Ding HF. p53 mediates DNA damaging druginduced apoptosis through a caspase-9-dependent pathway in SHSY5Y neuroblastoma cells. Mol Cancer Ther 2002;1:679-86.
41. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-81.
42. Fisher DE. Apoptosis in cancer therapy: Crossing the threshold. Cell 1994;78:539-42.
43. Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood 2001;98:2603-14.
44. Poulaki V, Mitsiades N, Romero ME, Tsokos M. Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and Bcl-2. Cancer Res 2001;61: 4864-72.
45. Lindsten T, Zong WX, Thompson CB. Defining the role of the Bcl-2 family of proteins in the nervous system. Neuroscientist 2005;11: 10-5.